Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 12/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136449 | 0.91 | KIT (0.51) | MAP3K11KITDYRK1A | |
| SCHEMBL18136451 | 0.79 | KIT (0.53) | MAP3K11KITDYRK1A | |
| SCHEMBL18136750 | 0.77 | KIT (0.51) | MAP3K11KITDYRK1A | |
| SCHEMBL18136754 | 0.76 | KIT (0.50) | MAP3K11KITDYRK1A | |
| SCHEMBL18206097 | 0.76 | KIT (0.50) | MAP3K11KITDYRK1A | |
| SCHEMBL18136828 | 0.74 | KIT (0.54) | KITDYRK1A | |
| SCHEMBL18136907 | 0.74 | KIT (0.50) | KITDYRK1A | |
| SCHEMBL18136450 | 0.74 | MAP3K11 (0.72) | MAP3K11KITDYRK1A | |
| SCHEMBL18136748 | 0.74 | PRKCI (0.54) | MAP3K11KITDYRK1A | |
| SCHEMBL18136911 | 0.73 | KIT (0.47) | KITDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | claimed |
| US-10160755-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| WO-2016164641-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160755-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K11, MAP4K2, PLK1 | MAP3K11 1/4885KIT 987/4885DYRK1A 395/4885 |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP4K2, PLK1 | MAP3K11 1/4885KIT 987/4885DYRK1A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.